{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Serna C"],"funding":["Intramural FDA HHS"],"pagination":["100064"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12856570"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["1"],"pubmed_abstract":["<h4>Background and purpose</h4>New approach methodologies (NAMs) including microphysiological systems in combination with human induced pluripotent stem cell (hiPSC)-derived neural cells and multielectrode array (MEA) have demonstrated utility for evaluating electrophysiological effects of CNS active compounds including those with potential seizurogenic liability. Here, we extend a neural NAM assay to assessment of an opioid agonist and reversal agent.<h4>Methods</h4>An in vitro human NAM composed of hiPSC-neurons and hiPSC-astrocytes coupled with MEA platform was used to assess spontaneous neural electrophysiology. Neural cells were cultured on MEA plates then treated with varying concentrations of the μ-opioid receptor agonist DAMGO (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin). Following DAM"],"journal":["NAM journal"],"pubmed_title":["Nonclinical human neural new approach methodologies (NAMs): Electrophysiological assessment of opioid agonist and antagonist combination."],"pmcid":["PMC12856570"],"funding_grant_id":["FD999999"],"pubmed_authors":["Bhardwaj B","Blinova K","Serna C","Feaster TK"],"additional_accession":[]},"is_claimable":false,"name":"Nonclinical human neural new approach methodologies (NAMs): Electrophysiological assessment of opioid agonist and antagonist combination.","description":"<h4>Background and purpose</h4>New approach methodologies (NAMs) including microphysiological systems in combination with human induced pluripotent stem cell (hiPSC)-derived neural cells and multielectrode array (MEA) have demonstrated utility for evaluating electrophysiological effects of CNS active compounds including those with potential seizurogenic liability. Here, we extend a neural NAM assay to assessment of an opioid agonist and reversal agent.<h4>Methods</h4>An in vitro human NAM composed of hiPSC-neurons and hiPSC-astrocytes coupled with MEA platform was used to assess spontaneous neural electrophysiology. Neural cells were cultured on MEA plates then treated with varying concentrations of the μ-opioid receptor agonist DAMGO (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin). Following DAM","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-19T04:58:33.64Z","creation":"2026-06-19T03:07:01.416Z"},"accession":"S-EPMC12856570","cross_references":{"pubmed":["41625301"],"doi":["10.1016/j.namjnl.2025.100064"]}}